METAVIA INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
METAVIA INC. (MTVA) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $401.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-30.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2020-03-30
- METAVIA INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2018 was $401.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2018-12-31 | $401.00K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |